On November 9, 2022 NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, and Abcam (AIM:ABC; NASDAQ:ABCM), a global life science company working together with researchers to advance science and enable faster breakthroughs, reported the expansion of their long-standing relationship with a new agreement to co-market Abcam antibodies for NanoString’s high-plex spatial multiomic solutions (Press release, Abcam, NOV 9, 2022, View Source [SID1234623565]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, Abcam RabMAb recombinant antibodies will be commercialized as part of the first 64-plex protein panel for NanoString’s CosMx Spatial Molecular Imager (SMI). Jointly developed and validated by NanoString and Abcam, the human immuno-oncology panel is the first on the market to combine high-plex spatial proteomic and transcriptomic analyses at single-cell and subcellular resolution. This provides unprecedented insights into immune cells, tumors and their neighborhood and aims to accelerate immune-oncology research supporting better understanding of clinical response and therapeutic resistance.
"We have partnered with Abcam to facilitate access to their broad portfolio of high-quality, validated antibodies to augment our CosMx protein panels," said Brad Gray, president and CEO of NanoString. "This relationship will further expand the depth and breadth of spatial biology offerings on NanoString instrumentation into new frontiers of human biology down to single-cell resolution— a true revolution in the spatial biology field."
"We are excited to enter a new phase of our relationship with NanoString. For the past six years, our teams have worked together to accelerate the development of novel technologies for the biomarker and clinical research community," said John Baker, SVP of Marketing of Abcam. "We are hopeful that these innovations will unlock the full potential of spatial biology and will ultimately help improve care for people with cancer".
NanoString will be hosting a symposium at the 37th Annual Meeting of the Society of Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Conference (SITC) (Free SITC Whitepaper) on Nov. 10 from 11:40 AM to 1:10 PM EST and will highlight the CosMx protein capability co-developed with Abcam. In the coming months NanoString and Abcam will co-host webinars and events to share insight on spatial biology in immuno-oncology and other applications such as neuroscience.